Intra-Cellular Therapies, Inc.
ITCI
Rank in Stocks
#1693
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Share Price
$131.87
Last synced: 2025-04-02
Market Cap
$12.68B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Intra-Cellular Therapies, Inc. (ITCI)
Category
Healthcare
Earnings for Intra-Cellular Therapies, Inc. (ITCI)
Earnings in Dec 2024 TTM: $-74.20M
According to Intra-Cellular Therapies, Inc. latest financial reports the company's current earnings are $-74.20M. In 2023 the company made an earning of $-139.04M, an increase over its 2022 earnings that were of $-256.25M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Intra-Cellular Therapies, Inc. from 2013 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-74.20M | 0.00% |
| 2024 | $-74.20M | -46.63% |
| 2023 | $-139.04M | -45.74% |
| 2022 | $-256.25M | -9.81% |
| 2021 | $-284.12M | 25.17% |
| 2020 | $-226.99M | 53.66% |
| 2019 | $-147.72M | -4.77% |
| 2018 | $-155.13M | 56.96% |
| 2017 | $-98.83M | -14.33% |
| 2016 | $-115.36M | 10.09% |
| 2015 | $-104.79M | 241.45% |
| 2014 | $-30.69M | 14.30% |
| 2013 | $-26.85M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -2,478.01% |
IN
|
